A new strategy for UK regenerative medicine

A new strategy for UK regenerative medicine

02 Apr 2012

The Technology Strategy Board and four UK Research Councils have unveiled a new roadmap for UK regenerative medicine research which includes £75m of investment into translational science.

A Strategy for UK Regenerative Medicine sets out clear objectives and a delivery plan focussed on translating our increased biological understanding into clinical impacts that will benefit both patients and the UK economy.

The strategy developed by the Medical Research Council (MRC), Engineering and Physical Sciences Research Council (EPSRC), Biotechnology and Biological Sciences Research Council (BBSRC), Economic and Social Research Council (ESRC) and the Technology Strategy Board takes stock of current capability and outlines the knowledge gaps and translational barriers that must be overcome if the UK is to remain at the forefront of global regenerative medicine over the next five years.

A key part of the strategy – a £25m investment into a new cross-Council UK Regenerative Medicine Platform (UKRMP) - has opened for applications. The UKRMP will work in close partnership with the  Technology Strategy Board Cell Therapy Catapult Centre  address the technical and scientific challenges associated with translating promising scientific discoveries in this area towards clinical impact. In doing so, the strategy aims to ensure full connectivity between the science base and those seeking to apply this for clinical and commercial impact, allowing the UK regenerative medicine community to operate as a single, globally competitive cluster.

For more information visit the Medical Research Council website

Download the strategy document here

This video requires flash version 7 or higher to play.

Last updated on Monday 02 April 2012 at 16:48

More like this

See more content in the <Medicines and healthcare> area

Copyright © 2013